Drug Profile
Research programme: salmonella-based cancer therapeutics - Tara Immuno-Oncology
Alternative Names: shIDO ST - Tara Immuno-Oncology; shIDO-ST - Tara immuno-OncologyLatest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator City of Hope National Medical Center
- Class Antineoplastics; Bacteria
- Mechanism of Action Fas ligand protein modulators; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Serine protease modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pancreatic cancer
Most Recent Events
- 25 Aug 2023 Discontinued - Preclinical for Pancreatic cancer in USA (unspecified route)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA
- 03 Nov 2015 Tara Immuno-Oncology in-licenses shIDO ST therapy from The City of Hope National Medical Center